Serotonin Receptor Found to Drive Bone Cancer Spread and Chemotherapy Failure

Osteosarcoma, the most common malignant bone tumor in children and young adults, has long frustrated oncologists with a grim pattern: even when surgery and chemotherapy appear to eliminate the primary tumor, the disease frequently returns as metastases, most often in the lungs, and the standard drug doxorubicin stops working. Now a team of researchers in China has traced both of these lethal behaviors to a single molecular culprit that most scientists had never seriously considered in bone cancer: HTR1D, a receptor better known for its role in serotonin signaling in the nervous system. The study, published in the Journal of Translational Medicine, not only maps an intricate circuit by which this receptor fuels cancer spread and drug resistance, but also identifies an existing plant-derived compound, poliumoside, that appears to jam the machinery at its most vulnerable point.

The research began with a straightforward clinical observation. When the team, led by corresponding authors Yu Qian and Yao Lu, examined tumor samples from osteosarcoma patients, they found that tumors with high levels of HTR1D expression were markedly more likely to have metastasized and to have responded poorly to doxorubicin-based chemotherapy. That correlation alone would not have been remarkable, since many proteins correlate with aggressive disease without actually causing it. What elevates this finding is the depth of the mechanistic work that followed. Using laboratory-grown osteosarcoma cells, the researchers showed that silencing HTR1D dramatically suppressed the cells’ ability to migrate and invade, the two cellular behaviors that underpin metastasis. More strikingly, when they implanted tumors into animal models, knocking down HTR1D reversed resistance to doxorubicin and curtailed the spread of the disease in living tissue.

To understand how a serotonin receptor exerts such power inside a bone tumor, the investigators turned to the tools of structural and molecular biology. Through co-immunoprecipitation, GST pull-down experiments, and precise point-mutation analysis, they demonstrated that HTR1D physically binds to a protein called GNAI1, an intracellular signaling partner. This interaction is not incidental: it activates the MAPK signaling pathway, a canonical growth-promoting cascade that cancer cells routinely hijack. The team also identified a specific tyrosine residue at position 137 of the HTR1D protein as critical; when they mutated this amino acid, the receptor lost much of its ability to drive metastatic behavior in the cells. This level of detail matters because it converts a correlation into a targetable mechanism, giving drug developers a defined molecular interface to attack.

Perhaps the most conceptually surprising discovery is that the pathway runs in a loop. The researchers found that c-MYC, one of the most notorious oncogenic transcription factors in all of cancer biology, sits upstream of HTR1D, binding to its gene and cranking up its production. But activated MAPK signaling, the very cascade that HTR1D triggers through GNAI1, in turn elevates c-MYC, which the team confirmed using luciferase reporter assays and immunofluorescence combined with fluorescence in situ hybridization on patient tissue sections. The result is a self-reinforcing positive feedback circuit: c-MYC makes more HTR1D, HTR1D activates MAPK through GNAI1, and MAPK makes more c-MYC. In effect, the tumor cell installs an accelerator that presses itself, explaining why osteosarcomas with high HTR1D behave so aggressively and why the phenotype is so difficult to dislodge with conventional chemotherapy alone.

The story does not end inside the tumor cell. Cancer is never a solo performance; it recruits the surrounding tissue, including immune cells, to serve its purposes. The researchers showed that HTR1D drives osteosarcoma cells to secrete CCL2, a chemokine that acts as a beacon for macrophages. When these immune cells arrive, CCL2 nudges them to polarize into the so-called M2 state, an immunosuppressive, tumor-promoting identity that helps cancers evade attack and remodel tissue to favor invasion. The team verified this through cell co-culture experiments in which depleting CCL2 impaired the polarization of tumor-associated macrophages, and through flow cytometry that characterized the M2 population. In animal models, depleting CCL2 inhibited metastasis and improved the sensitivity of tumors to doxorubicin, confirming that this immune axis is not a bystander but an active participant in treatment failure.

Then comes the twist that gives the circuit its name. The M2-polarized macrophages, once converted to the tumor’s side, produce serotonin, the 5-HT that HTR1D is built to detect. This serotonin flows back to the tumor cells and sustains the chemoresistant state, closing a second loop that spans two different cell types. The researchers noted that osteosarcoma cell lines themselves show serotonin synthesis potential according to data from the Human Protein Atlas, suggesting the tumor microenvironment is saturated with the ligand this receptor craves. In other words, the cancer engineers its own supply chain: it summons macrophages with CCL2, converts them into serotonin factories, and then uses the serotonin to keep its own pro-survival signaling humming. It is a textbook example of the increasingly appreciated principle that tumors do not merely tolerate their microenvironment; they actively reprogram it into a supporting organ.

Against this elaborate biological backdrop, the therapeutic finding is what makes the paper travel beyond the specialty literature. Rather than trying to block serotonin itself, which would cause widespread neurological and cardiovascular side effects, the team searched for a small molecule that could competitively disrupt the physical handshake between HTR1D and GNAI1. Using computer-simulated screening of compound libraries, they identified poliumoside, a natural glycoside compound, as a candidate blocker. Subsequent experiments confirmed that poliumoside suppresses the HTR1D-GNAI1-MAPK signaling axis in osteosarcoma cells, dampens their metastatic behavior in vitro, and reduces proliferation markers such as Ki67 in xenograft tumors in vivo. Because the compound targets the protein-protein interaction rather than the receptor’s serotonin-binding site, it offers a degree of specificity that direct receptor antagonists would struggle to achieve.

The dual nature of the target is what excites many observers of translational oncology. Drugs that address only metastasis leave chemoresistance intact, and drugs that resensitize tumors to chemotherapy do nothing to stop cells from already spreading. A single intervention that collapses both phenotypes, by severing the feedback loop that drives them in parallel, could in principle change the trajectory of the disease at its root. The authors suggest that poliumoside, or derivatives built upon its scaffold, could be developed as a dual-action therapeutic candidate to be used alongside doxorubicin, restoring the potency of the standard regimen while simultaneously choking off the metastatic program. For a cancer in which five-year survival for metastatic cases remains dismal despite decades of multimodal treatment, any strategy that attacks two vulnerabilities at once is worth serious attention.

Caveats remain, as they always do at this stage of translation. The work rests on cell lines, patient tissue correlations, and xenograft models, which are powerful but imperfect proxies for human disease; poliumoside’s pharmacokinetics, toxicity profile, and efficacy in humans have not yet been established, and the study was funded by regional research grants including the Scientific Research Project of Suqian Health Commission and the Development Fund of The Affiliated Hospital of Xuzhou Medical University. Still, the paper delivers something rare: a complete mechanistic arc from a clinically observed biomarker, through a defined intracellular feedback circuit and an intercellular immune axis, to a druggable interface and a candidate compound already in hand. It also adds HTR1D to a growing list of neural signaling molecules that cancers co-opt, reinforcing the idea that the boundary between neurobiology and oncology is far blurrier than textbooks once suggested. If follow-up studies validate the approach, the humble serotonin receptor may become one of the most consequential targets in bone cancer therapy.

Subject of Research: The role of the serotonin receptor HTR1D in osteosarcoma metastasis and doxorubicin resistance

Article Title: HTR1D triggers osteosarcoma metastasis and doxorubicin resistance via c-MYC/MAPK feedback and CCL2/5-HT-mediated M2 polarization

Article References: Shi, C., Li, J., Wang, Y., Zeng, X., Wang, Y., Liu, G., Huang, P., Xu, Q., Wang, M., Qian, Y., & Lu, Y. (2026). HTR1D triggers osteosarcoma metastasis and doxorubicin resistance via c-MYC/MAPK feedback and CCL2/5-HT-mediated M2 polarization. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09048-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09048-3

Keywords: osteosarcoma, HTR1D, doxorubicin resistance, metastasis, MAPK pathway, c-MYC, GNAI1, CCL2, serotonin, M2 macrophage polarization, poliumoside, tumor microenvironment